Dossier assessment
Doravirine (HIV infection) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Doravirine (HIV infection) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Doravirine (HIV infection) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Indication:
Adults infected with HIV-1
Result of dossier assessment:
Added benefit not proven for treatment-naive or pretreated patients
Additional information
Federal Joint Committee (G-BA)
2019-07-04 A G-BA decision was published.
Project details
- Project no.
- A19-07
- Commission
- Commission awarded on 14.01.2019 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Immune system and infections
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Doravirine (HIV infection in adolescents) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed